ALKD5F3 DETECTS ELIGIBILITY FOR TYROSINE KINASE INHIBITOR (TKI) THERAPY PRIMARILY IN INDIVIDUALS WITH PULMONARY ADENOCARCINOMA BY IDENTIFYING ALK FUSION PROTEINS.
Why book with us?
Free and On Schedule Sample Collection
24/7 Service
Affordable
Quick and Accurate Reports
SUBMIT TISSUE IN 10% FORMAL-SALINE OR FORMALIN FIXED PARAFFIN EMBEDDED TISSUE BLOCK. SHIP AT ROOM TEMPERATURE. PROVIDE A COPY OF THE HISTOPATHOLOGY REPORT, SITE OF BIOPSY AND CLINICAL HISTORY.
IHC
REPORT ON 4TH DAY EVENING 7PM
PROVIDE A COPY OF THE HISTOPATHOLOGY REPORT, SITE OF BIOPSY AND CLINICAL HISTORY.